Theralase Technologies Inc (TLT_CDNX)
TLT_CDNX moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How TLT_CDNX actually reacts to news — the realized, point-in-time move the market made, measured across 48 labeled events over the last three years with zero look-ahead.
TLT_CDNX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 18% | 33 |
| 30-min | 0.00% | 18% | 33 |
| 60-min | 0.00% | 18% | 34 |
| to close | 0.00% | 46% | 35 |
| Middle 50% of TLT_CDNX reactions | -1.96% to 0.00% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 48 |
Half of all Theralase Technologies Inc news events land between -1.96% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TLT_CDNX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TLT_CDNX's baseline. Nothing else.
Recent TLT_CDNX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Canadian Investment Regulatory Organization Trade Resumption - TLT | Press release | Canada Newswire | — | — | |
| Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer | Press release | Business Wire | — | — | |
| Canadian Investment Regulatory Organization Trading Halt - TLT | Press release | Canada Newswire | — | — | |
| CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes | Press release | ACCESS Newswire | — | — | |
| Theralase(R) Demonstrates Effective Treatment of Herpes | Press release | ACCESS Newswire | — | — | |
| Theralase(R) Releases Latest Research on Inactivation of Herpes Simplex Viruses | Press release | ACCESS Newswire | — | — | |
| Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting | Press release | Accesswire | — | — | |
| Theralase(R) Launches Three New Clinical Study Sites in USA | Press release | Accesswire | — | — | |
| Theralase(R) Launches New Clinical Study Site in Canada | Press release | Accesswire | — | — | |
| Theralase(R) Release’s 3Q2024 Financial Statements | Press release | Accesswire | — | — | |
| Theralase(R) Closes Non-Brokered Private Placement | Press release | Accesswire | — | — | |
| Theralase(R) Extends Warrants | Press release | Accesswire | — | — | |
| Theralase(R) Provides Update on Bladder Cancer Clinical Study | Press release | Accesswire | — | — | |
| Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options | Press release | Accesswire | +0.00% | +0.00% | |
| Theralase(R) Extends Warrants | Press release | Accesswire | +0.00% | +2.78% | |
| Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus | Press release | Accesswire | +0.00% | +2.94% | |
| Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer | Press release | Accesswire | +0.00% | +0.00% | |
| Canadian Investment Regulatory Organization Trading Halt - TLT.WT | Press release | Canada Newswire | — | +2.70% | |
| Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug | Press release | Accesswire | +0.00% | +2.63% | |
| Theralase(R) Release’s 2Q2024 Financial Statements | Press release | Accesswire | +0.00% | -2.70% | |
| Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement | Press release | Accesswire | +0.00% | -5.41% | |
| Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy | Press release | Accesswire | +0.00% | -5.13% | |
| Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically | Press release | Accesswire | +0.00% | -5.13% | |
| Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically | Press release | Accesswire | -2.38% | -7.14% | |
| Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R) | Press release | Accesswire | +0.00% | +2.63% | |
| Rutherrin(R) Increases Efficacy of Chemotherapy | Press release | Accesswire | — | +10.26% | |
| Ruvidar(TM) Enhances Efficacy of Cancer Drug | Press release | Accesswire | +0.00% | +0.00% | |
| Theralase(R) Successfully Destroys Lung Cancer | Press release | Accesswire | +5.00% | -5.00% | |
| Theralase(R) Technology Effective in Virus Inactivation | Press release | Accesswire | +3.33% | +23.33% | |
| Theralase(R) Release's 1Q2024 Financial Statements | Press release | Accesswire | +0.00% | -3.33% | |
| Theralase(R) Expands Clinical Team | Press release | Accesswire | +0.00% | -3.03% | |
| Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement | Press release | Accesswire | +0.00% | +3.13% | |
| Theralase(R) Granted Canadian Cancer Vaccine Patent | Press release | Accesswire | +0.00% | +9.09% | |
| Theralase(R) Release's 4Q2023 Interim Financial Statements | Press release | Accesswire | +0.00% | -5.71% | |
| Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association | Press release | Accesswire | +0.00% | +9.09% | |
| Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease | Press release | Accesswire | +2.56% | +2.56% | |
| Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study | Press release | Accesswire | +0.00% | +5.26% | |
| Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement | Press release | Accesswire | +0.00% | +17.14% | |
| Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study | Press release | Accesswire | +0.00% | +0.00% | |
| Theralase Release’s 3Q2023 Interim Financial Statements | Press release | Accesswire | -7.89% | -2.63% | |
| Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement | Press release | Accesswire | -7.89% | -2.63% | |
| Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing | Press release | Accesswire | +0.00% | +0.00% | |
| Theralase(R) Announces Brokered LIFE Financing | Press release | Accesswire | -4.76% | -2.38% | |
| Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study | Press release | Accesswire | +1.96% | +1.96% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TLT_CDNX section they belong to.
Where else TLT_CDNX is measured.
TLT_CDNX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Arch Biopartners Inc (ARCH_CDNX) | 48 | -0.59% | 19% |
| SINO BIOPHARM ORD (SBMFF) | 48 | 0.00% | 4% |
| DEMANT HLDG U/ADR (WILYY) | 48 | 0.00% | 18% |
| HLS THERAPEUTICS INC (HLTRF) | 47 | 0.00% | 24% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Theralase Technologies Inc's median reaction calculated?
Every labeled TLT_CDNX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 48 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 18% of TLT_CDNX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TLT_CDNX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.